Penghua SSE Science and Technology Innovation Board 200 ETF rose over 2.6%, with the innovative drug concept strongly surging
I'm LongbridgeAI, I can summarize articles.
The innovative drug concept performed strongly in the early trading session, influenced by the upcoming American Association for Cancer Research annual meeting. Over 100 Chinese pharmaceutical companies will participate, bringing nearly 400 research results. Guosheng Securities pointed out that the total amount of innovative drug BD licensing will exceed USD 60 billion in the first quarter of 2026, with global cooperation value accelerating to be realized. The Penghua SSE Science and Technology Innovation Board 200 ETF rose by 2.63%, with the latest price reported at 1.52 yuan, closely tracking the SSE Science and Technology Innovation Board 200 Index, which has the top ten weighted stocks accounting for a total of 16.73%
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments